Cowen Starts Allena Pharmaceuticals (ALNA) at Outperform

Cowen initiates coverage on Allena Pharmaceuticals (NASDAQ: ALNA) with a Outperform rating.

Analyst Ritu Baral said the company has a promising platform to address unmet need in renal-metabolic disorders, and we see compelling POC Ph2 data from lead candidate ALLN-177 in enteric hyperoxaluria.

Baral is optimistic for success of the planned Ph3 trials of '177 in enteric hyperoxaluria, expected to initiate in 1Q18 and 2H18, with data expected in 2019.

For an analyst ratings summary and ratings history on Allena Pharmaceuticals click here. For more ratings news on Allena Pharmaceuticals click here.

Shares of Allena Pharmaceuticals closed at $13.13 yesterday.

You May Also Be Interested In

• Citi Upgrades Grupo Aeroportuario del Pacifico SAB de CV (GAPB:MM) (PAC) to Buy
• Taiwan Semi (TSM) PT Raised to $500 at DA Davidson Following Q2 Earnings, Revenue Beat
• Citizens Financial Group (CFG) PT Raised to $85 at DA Davidson